Overactive Bladder Forecast in 12 Major Markets 2017-2027

February 2017 | 48 pages | ID: OB0D7526CEAEN
Black Swan Analysis limited

Abstracts

An epiretinal membrane (ERM) is a thin sheet of fibrous tissue that develops on the surface of the macula and can cause problems with central vision.

This report provides the current prevalent population for Epiretinal Membrane across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Australia and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Epiretinal Membrane have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The following are considered risk factors for developing ERMs:

• Age (65+)
• Cataract surgery
• Other eye surgery
• Posterior uveitis
• Eye diseases
• Retinal tear/detachment
• Vitreomacular adhesion and traction
• Diabetic retinopathy

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Epiretinal Membrane market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Epiretinal Membrane and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Epiretinal Membrane’s prevalent population.
• Identify sub-populations within Epiretinal Membrane which require treatment.
• Gain an understanding of the specific markets that have the largest number of Epiretinal Membrane patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key comorbid conditions/Features associated with the disease
Methodology for quantification of patient numbers
Top-line prevalence for Overactive Bladder
Features of Overactive Bladder patients
Prevalence of clinically diagnosed OAB
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Criteria for the Diagnosis of Overactive Bladder
Prevalence of Overactive Bladder, total (000s)
Prevalence of Overactive Bladder, males (000s)
Prevalence of Overactive Bladder, females (000s)
Severity of Symptom Bother, total (000s)
OAB patients with Nocturia, total (000s)
OAB patients with Urgency, total (000s)
OAB patients with Frequency, total (000s)
OAB patients with UUI, total (000s)
Prevalence of Clinically diagnosed OAB, total (000s)
Prevalence of Clinically diagnosed OAB, males (000s)
Prevalence of Clinically diagnosed OAB, females (000s)
Clinically diagnosed OAB Urge Incontinence status, total (000s)
Clinically diagnosed OAB patients by symptoms, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
USA Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Canada Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Canada Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
France Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
France Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Germany Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Germany Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Italy Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Italy Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Spain Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Spain Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
UK Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
UK Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Brazil Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Brazil Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Japan Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Japan Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
India Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
India Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
China Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
China Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Russia Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
Russia Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)